Injected version of Eisai/Biogen Alzheimer’s drug effective

BOSTON--An injected version of Eisai and Biogen’s Alzheimer’s drug Leqembi works as well as the current intravenous ...

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive ...

Leqembi® Pen subcutaneous formulation approved in Japan

BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new ...
FierceBiotech

Eisai to drop up to $15M on C2N Diagnostics to boost the reach of Alzheimer's disease blood tests

After netting a historic FDA drug nod in Alzheimer’s disease last year—and seeing a relatively slow commercial rollout in the time since—Eisai is now re-upping its investment in Alzheimer’s blood test ...

New Alzheimer's Drug

Eisai announced on the 16th that it has received approval from the Ministry of Health, Labour and Welfare for a subcutaneous ...
FiercePharma

Eisai on your hi-fi: Leqembi maker supports creation of Alzheimer's podcast miniseries

Eisai has added another strand to its budding podcast network, bankrolling the “Rethinking Alzheimer's Disease” miniseries to spread information about the prevention and diagnosis of the condition.
MarketScreener

Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)

TOKYO, Sept 15, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into an agreement (the "Agreement") with Osaka Prefecture ...

Eisai expects 1,500 Alzheimer’s patients in China launch, sees ‘huge’ growth

CHICAGO/SHANGHAI--Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later ...
RTTNews

Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease

Drug makers Biogen Inc. ( BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK,4523.T,EII.SG) announced Wednesday that Japan has approved LEQEMBI Pen, the subcutaneous (SC) formulation of the anti-amyloid beta ...
CNBC

Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says

Drugmaker Eisai said the Veterans Health Administration will cover its Alzheimer's treatment Leqembi, which costs $26,500 per year. Veterans with early Alzheimer's who meet certain VHA criteria can ...
FiercePharma

Eisai hit with ransomware attack, launches investigation into possible data leaks

Eisai is the latest drugmaker to be hit with a ransomware attack. The Japanese company said it “immediately” set up a company-wide task force after suffering a cyberattack Saturday night. Now, it's ...
MarketScreener

LEQEMBI(R) Pen (Subcutaneous Formulation of LEQEMBI(R)) Approved in Japan for the Treatment of Early Alzheimer's Disease

Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (AB) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan as a new route of ...